AdAlta CEO Sam Cobb spoke with Proactive Investors during her recent trip to San Francisco to attend Biotech Showcase, meeting with investors and pharmaceutical companies.
Take a look at the brief interview below which provides an update on the progress of AdAlta’s lead program, AD-214, a novel i-body therapy for the treatment of the lung condition, Idiopathic Pulmonary Fibrosis.
If you would like to stay informed of AdAlta’s progress, subscribe to receive updates here.